Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals

The pandemic unleashed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 500 million people worldwide and caused more than 6 million deaths. Cellular and humoral immunity induced by infection or immunization are key factors in controlling the viral burden and avo...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of allergy and clinical immunology. Global Vol. 2; no. 2; p. 100083
Main Authors:	Fernandes, Edgar Ruz, Taminato, Monica, de Souza Apostolico, Juliana, Gabrielonni, Maria Cristina, Lunardelli, Victoria Alves Santos, Maricato, Juliana Terzi, Andersen, Monica Levy, Tufik, Sergio, Rosa, Daniela Santoro
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.05.2023 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology Elsevier
Subjects:	antibodies ChAdOx1 nCoV-19 CoronaVac COVID-19 SARS-CoV-2 COVID-19 SARS-CoV-2 AU RBD antibodies CoronaVac ChAdOx1 nCoV-19 sVNT RBD, Receptor-binding domain SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 AU, Arbitrary units sVNT, Surrogate Virus Neutralization Test COVID-19, Coronavirus disease 2019
ISSN:	2772-8293, 2772-8293
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!